Clinical Trial Update: Study of Ramucirumab in Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of ramucirumab in ovarian cancer and related gynecologic cancers has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Carcinoma

Drugs mentioned

• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-06-18